Middleton & Co. Inc. MA Lowers Holdings in Pfizer Inc. (NYSE:PFE)

Middleton & Co. Inc. MA trimmed its position in Pfizer Inc. (NYSE:PFE) by 22.0% in the 3rd quarter, according to its most recent 13F filing with the Securities and Exchange Commission. The firm owned 8,158 shares of the biopharmaceutical company’s stock after selling 2,301 shares during the quarter. Middleton & Co. Inc. MA’s holdings in Pfizer were worth $236,000 at the end of the most recent reporting period.

Other hedge funds have also made changes to their positions in the company. Olistico Wealth LLC purchased a new stake in shares of Pfizer in the 2nd quarter worth $25,000. MFA Wealth Advisors LLC purchased a new stake in shares of Pfizer in the 2nd quarter worth $29,000. Quarry LP purchased a new stake in shares of Pfizer during the 2nd quarter worth $31,000. Trivant Custom Portfolio Group LLC lifted its stake in shares of Pfizer by 100.0% during the 1st quarter. Trivant Custom Portfolio Group LLC now owns 1,200 shares of the biopharmaceutical company’s stock worth $33,000 after purchasing an additional 600 shares during the last quarter. Finally, Financial Connections Group Inc. purchased a new stake in shares of Pfizer during the 2nd quarter worth $34,000. 68.36% of the stock is currently owned by hedge funds and other institutional investors.

Wall Street Analyst Weigh In

A number of equities research analysts recently weighed in on PFE shares. Barclays upped their price objective on Pfizer from $30.00 to $32.00 and gave the stock an “equal weight” rating in a research note on Wednesday, July 31st. Wells Fargo & Company upped their price objective on Pfizer from $28.00 to $30.00 and gave the stock an “equal weight” rating in a research note on Wednesday, July 31st. UBS Group upped their price objective on Pfizer from $30.00 to $31.00 and gave the stock a “neutral” rating in a research note on Wednesday, July 31st. Daiwa Capital Markets upgraded Pfizer from a “neutral” rating to an “outperform” rating and upped their price objective for the stock from $28.00 to $34.00 in a research note on Wednesday, August 7th. Finally, Sanford C. Bernstein initiated coverage on Pfizer in a research note on Thursday, October 17th. They issued a “market perform” rating and a $32.00 price target for the company. Eight research analysts have rated the stock with a hold rating, six have assigned a buy rating and one has issued a strong buy rating to the company. According to MarketBeat.com, the stock has an average rating of “Moderate Buy” and an average price target of $33.58.

Pfizer Stock Down 0.7 %

Shares of PFE stock opened at $28.45 on Friday. The stock’s 50-day simple moving average is $29.07 and its 200-day simple moving average is $28.49. The company has a debt-to-equity ratio of 0.65, a quick ratio of 0.60 and a current ratio of 0.86. The firm has a market capitalization of $161.22 billion, a PE ratio of -61.87, a P/E/G ratio of 1.01 and a beta of 0.67. Pfizer Inc. has a fifty-two week low of $25.20 and a fifty-two week high of $31.54.

Pfizer (NYSE:PFE) last announced its quarterly earnings data on Tuesday, July 30th. The biopharmaceutical company reported $0.60 earnings per share for the quarter, beating analysts’ consensus estimates of $0.46 by $0.14. The business had revenue of $13.28 billion for the quarter, compared to analyst estimates of $12.96 billion. Pfizer had a positive return on equity of 8.42% and a negative net margin of 4.66%. The company’s revenue was up 2.1% on a year-over-year basis. During the same period in the prior year, the company earned $0.67 earnings per share. Equities analysts expect that Pfizer Inc. will post 2.67 earnings per share for the current year.

Pfizer Dividend Announcement

The company also recently disclosed a quarterly dividend, which will be paid on Monday, December 2nd. Stockholders of record on Friday, November 8th will be issued a $0.42 dividend. This represents a $1.68 dividend on an annualized basis and a dividend yield of 5.91%. The ex-dividend date is Friday, November 8th. Pfizer’s dividend payout ratio is presently -365.21%.

About Pfizer

Pfizer Inc discovers, develops, manufactures, markets, distributes, and sells biopharmaceutical products in the United States, Europe, and internationally. The company offers medicines and vaccines in various therapeutic areas, including cardiovascular metabolic, migraine, and women's health under the Eliquis, Nurtec ODT/Vydura, Zavzpret, and the Premarin family brands; infectious diseases with unmet medical needs under the Prevnar family, Abrysvo, Nimenrix, FSME/IMMUN-TicoVac, and Trumenba brands; and COVID-19 prevention and treatment, and potential future mRNA and antiviral products under the Comirnaty and Paxlovid brands.